Celcuity to Unveil Phase 3 Trial Results for Gedatolisib in Advanced Breast Cancer
Event summary
- Celcuity will host a conference call on June 2, 2026, to discuss results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 trial.
- The trial evaluates gedatolisib regimens in HR+/HER- advanced breast cancer patients.
- Gedatolisib is a kinase inhibitor targeting the PI3K/AKT/mTOR pathway.
- VIKTORIA-1 has reported detailed results for PIK3CA wild-type tumors and topline results for PIK3CA mutant-type tumors.
- Celcuity is also conducting the Phase 3 VIKTORIA-2 trial and a Phase 1b/2 trial for prostate cancer.
The big picture
Celcuity's Phase 3 trial results for gedatolisib come at a critical juncture in the oncology space, where targeted therapies are increasingly becoming the standard of care. The company's focus on the PI3K/AKT/mTOR pathway positions it within a competitive but growing segment of precision medicine. Success in this trial could accelerate gedatolisib's path to market, while failure may necessitate a strategic pivot in Celcuity's development pipeline.
What we're watching
- Clinical Efficacy
- How the Phase 3 trial results for the PIK3CA mutant cohort will impact the regulatory pathway for gedatolisib.
- Market Differentiation
- Whether Celcuity can position gedatolisib as a differentiated therapy in the competitive landscape of HR+/HER- advanced breast cancer treatments.
- Pipeline Progress
- The pace at which Celcuity advances its ongoing trials, including VIKTORIA-2 and the Phase 1b/2 trial for prostate cancer.
Related topics